NCT02665598

Brief Summary

Posterior Reversible Encephalopathy Syndrome (PRES) is a clinical-radiological entity, which is associated with a variety of clinical conditions. The imaging and clinical findings are typically reversible, but many patients still have permanent neurological sequelae with a fatal outcome. Up to now there are no consistent conclusions about the factors that affecting its prognosis. The objective of our study is to discuss the effects of different causes, different imaging findings and laboratory parameters on the prognosis of PRES and deepen the understanding of the nature of PRES. This will contribute to predict the prognosis of patients with PRES and to further investigate the pathogenesis of PRES so as to guide the clinical treatment and follow-up evaluation. A multi-center retrospective case study will be performed from January 2016 to July 2017 and a total of 400 patients who meet the criteria for PRES diagnosis from 10 sub-centers are anticipated included in this research. Patients will be divided into several subgroups according to the etiology. Date will be collected from the clinical records,imaging and laboratory data of the patients, including demographic data, clinical data, imaging findings, laboratory parameters and follow-up data. During the follow-up, MRI and blood biochemical examination will be performed once more. The imaging findings of the patients will be assessed by two neuroimaging physicians, any difference between them will be agreed upon by consensus. Prognosis of the patients will be assessed by using the modified Rankin scale (mRS) scores. All of the above data is saved into the database. In this study we will review etiologies and imaging findings, laboratory and follow-up data of the patients we selected. Univariate and multivariate analysis will be performed within the group and between groups according to the subgroups. Then we will discuss the connection between different causes, different imaging findings and laboratory parameters and the prognosis of posterior reversible encephalopathy syndrome.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
400

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Apr 2016

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 3, 2016

Completed
25 days until next milestone

First Posted

Study publicly available on registry

January 28, 2016

Completed
2 months until next milestone

Study Start

First participant enrolled

April 1, 2016

Completed
7.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2023

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2024

Completed
Last Updated

August 4, 2022

Status Verified

August 1, 2022

Enrollment Period

7.3 years

First QC Date

January 3, 2016

Last Update Submit

August 2, 2022

Conditions

Keywords

Posterior Reversible Encephalopathy Syndrome,Prognosis

Outcome Measures

Primary Outcomes (1)

  • Quantitative assessment of short term and long term prognosis of PRES patients by mRS score

    within six months

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

The patients with complete inpatient clinical records who meet the inclusion criteria from January 2016 to July 2015 will be included in this research.

You may qualify if:

  • Patients who meet the criteria for PRES diagnosis:(1)typical symptoms and signs consistent with PRES, such as headache, seizures, mental status changes, visual disturbances or focal neurological deficits;(2)patients with typical or atypical imaging manifestations of PRES;(3)patients who have known risk factors of PRES.
  • Patients with definite prognosis will be included.
  • Patients with complete inpatient medical records will be included.

You may not qualify if:

  • Patients with edema secondary to ischemia, hemorrhage, infection, inflammation, or space occupying lesions will be excluded.
  • Patients with absent or non-diagnostic MRI will be excluded.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Weihai Municipal Hospital

Weihai, Shandong, 264200, China

RECRUITING

Related Publications (15)

  • Alhilali LM, Reynolds AR, Fakhran S. A multi-disciplinary model of risk factors for fatal outcome in posterior reversible encephalopathy syndrome. J Neurol Sci. 2014 Dec 15;347(1-2):59-65. doi: 10.1016/j.jns.2014.09.019. Epub 2014 Sep 22.

  • Merayo-Chalico J, Apodaca E, Barrera-Vargas A, Alcocer-Varela J, Colunga-Pedraza I, Gonzalez-Patino A, Arauz A, Abud-Mendoza C, Martinez-Martinez M, Gomez-Martin D. Clinical outcomes and risk factors for posterior reversible encephalopathy syndrome in systemic lupus erythematosus: a multicentric case-control study. J Neurol Neurosurg Psychiatry. 2016 Mar;87(3):287-94. doi: 10.1136/jnnp-2014-310145. Epub 2015 Mar 24.

  • Legriel S, Schraub O, Azoulay E, Hantson P, Magalhaes E, Coquet I, Bretonniere C, Gilhodes O, Anguel N, Megarbane B, Benayoun L, Schnell D, Plantefeve G, Charpentier J, Argaud L, Mourvillier B, Galbois A, Chalumeau-Lemoine L, Rivoal M, Durand F, Geffroy A, Simon M, Stoclin A, Pallot JL, Arbelot C, Nyunga M, Lesieur O, Troche G, Bruneel F, Cordoliani YS, Bedos JP, Pico F; Critically III Posterior Reversible Encephalopathy Syndrome Study Group (CYPRESS). Determinants of recovery from severe posterior reversible encephalopathy syndrome. PLoS One. 2012;7(9):e44534. doi: 10.1371/journal.pone.0044534. Epub 2012 Sep 14.

  • Liman TG, Bohner G, Endres M, Siebert E. Discharge status and in-hospital mortality in posterior reversible encephalopathy syndrome. Acta Neurol Scand. 2014 Jul;130(1):34-9. doi: 10.1111/ane.12213. Epub 2013 Dec 13.

  • Moon SN, Jeon SJ, Choi SS, Song CJ, Chung GH, Yu IK, Kim DH. Can clinical and MRI findings predict the prognosis of variant and classical type of posterior reversible encephalopathy syndrome (PRES)? Acta Radiol. 2013 Dec;54(10):1182-90. doi: 10.1177/0284185113491252. Epub 2013 Jul 15.

  • Pande AR, Ando K, Ishikura R, Nagami Y, Takada Y, Wada A, Watanabe Y, Miki Y, Uchino A, Nakao N. Clinicoradiological factors influencing the reversibility of posterior reversible encephalopathy syndrome: a multicenter study. Radiat Med. 2006 Dec;24(10):659-68. doi: 10.1007/s11604-006-0086-2. Epub 2006 Dec 25.

  • Pereira PR, Pinho J, Rodrigues M, Rocha J, Sousa F, Amorim J, Ribeiro M, Rocha J, Ferreira C. Clinical, imagiological and etiological spectrum of posterior reversible encephalopathy syndrome. Arq Neuropsiquiatr. 2015 Jan;73(1):36-40. doi: 10.1590/0004-282X20140176. Epub 2015 Jan 1.

  • Prasad N, Gulati S, Gupta RK, Kumar R, Sharma K, Sharma RK. Is reversible posterior leukoencephalopathy with severe hypertension completely reversible in all patients? Pediatr Nephrol. 2003 Nov;18(11):1161-6. doi: 10.1007/s00467-003-1243-9. Epub 2003 Sep 19.

  • Singh RR, Ozyilmaz N, Waller S, U-King-Im JM, Lim M, Siddiqui A, Sinha MD. A study on clinical and radiological features and outcome in patients with posterior reversible encephalopathy syndrome (PRES). Eur J Pediatr. 2014 Sep;173(9):1225-31. doi: 10.1007/s00431-014-2301-y. Epub 2014 Apr 16.

  • Postma IR, Slager S, Kremer HP, de Groot JC, Zeeman GG. Long-term consequences of the posterior reversible encephalopathy syndrome in eclampsia and preeclampsia: a review of the obstetric and nonobstetric literature. Obstet Gynecol Surv. 2014 May;69(5):287-300. doi: 10.1097/OGX.0000000000000069.

  • Liman TG, Bohner G, Heuschmann PU, Endres M, Siebert E. The clinical and radiological spectrum of posterior reversible encephalopathy syndrome: the retrospective Berlin PRES study. J Neurol. 2012 Jan;259(1):155-64. doi: 10.1007/s00415-011-6152-4. Epub 2011 Jun 30.

  • Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015 Sep;14(9):914-925. doi: 10.1016/S1474-4422(15)00111-8. Epub 2015 Jul 13.

  • Gao B, Liu FL, Zhao B. Association of degree and type of edema in posterior reversible encephalopathy syndrome with serum lactate dehydrogenase level: initial experience. Eur J Radiol. 2012 Oct;81(10):2844-7. doi: 10.1016/j.ejrad.2011.12.010. Epub 2011 Dec 29.

  • Gao B, Yu BX, Li RS, Zhang G, Xie HZ, Liu FL, Lv C. Cytotoxic Edema in Posterior Reversible Encephalopathy Syndrome: Correlation of MRI Features with Serum Albumin Levels. AJNR Am J Neuroradiol. 2015 Oct;36(10):1884-9. doi: 10.3174/ajnr.A4379. Epub 2015 Jul 2.

  • Bo G, Hui L, Feng-Li L, Cui L. Relationships between edema degree and clinical and biochemical parameters in posterior reversible encephalopathy syndrome: a preliminary study. Acta Neurol Belg. 2012 Sep;112(3):281-5. doi: 10.1007/s13760-012-0060-y. Epub 2012 Mar 24.

MeSH Terms

Conditions

Posterior Leukoencephalopathy Syndrome

Condition Hierarchy (Ancestors)

Hypertensive EncephalopathyIntracranial HypertensionBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesLeukoencephalopathies

Study Officials

  • Bo Gao, MD

    STUDY CHAIR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 3, 2016

First Posted

January 28, 2016

Study Start

April 1, 2016

Primary Completion

July 1, 2023

Study Completion

January 1, 2024

Last Updated

August 4, 2022

Record last verified: 2022-08

Data Sharing

IPD Sharing
Will share

Locations